Daewon Pharmaceutical's Phase 3 Success for 'Fodopraazan'; Competition Heats Up in Expanding P-CAB Market
Predicted impact: Medium
Phase 3 success already reported and priced in; drug is key to a company worth about 0.17T won.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.